PDCD5 Antibody

What is PDCD5 and what are its key cellular functions?

PDCD5 (also known as TFAR19) was first identified as a gene upregulated in TF-1 cells undergoing apoptosis . The protein has a compact core structure with two mobile alpha-helices at the N-terminal region and a flexible unstructured C-terminal domain . PDCD5 promotes programmed cell death in various cell types in response to different stimuli and enhances TAJ/TROY-induced paraptosis-like cell death . Recent research has demonstrated that PDCD5 interacts with Tip60 histone acetyltransferase, enhancing its stability and activity in both basal and UV-induced conditions . This interaction promotes p53-dependent apoptosis through enhanced HAT activity and p53 acetylation at K120 .

What types of PDCD5 antibodies are available and what are their characteristics?

Several PDCD5 antibodies are commercially available with different specifications:

When selecting an antibody, consider the specific application requirements, target species, and whether you need to target a specific domain of the protein.

What is the expected molecular weight of PDCD5 in Western blot applications?

The calculated molecular weight of PDCD5 is 14 kDa (125 amino acids) . In Western blot applications, PDCD5 is typically observed as a band at approximately 14-15 kDa, though additional bands at 18 kDa and 20 kDa have been reported in some cell lines . When working with new cell lines, it's advisable to validate the specific band pattern. For instance, Western blot analysis of EL4 mouse lymphoblast cell lysates showed bands at both 18 kDa and 20 kDa , while detection in HEK293, EL-4, and L6 cell lines revealed a specific band at approximately 15 kDa .

What are the optimal conditions for Western blot detection of PDCD5?

For optimal Western blot detection of PDCD5:

• Sample preparation:

  • Use cell lines with known PDCD5 expression such as HEK293, A549, PC-3, or EL-4

  • Load 15-50 μg of total protein per lane (15 μg was sufficient for EL4 cell lysate)

• Gel and transfer conditions:

  • Use 12-15% SDS-PAGE gels due to PDCD5's low molecular weight

  • PVDF membrane is recommended for transfer

• Antibody dilutions:

  • Primary antibody: 1:500-1:1000 for Western blot applications

  • For specific antibodies, such as Mouse Anti-Human/Mouse/Rat PDCD5 Polyclonal Antibody, 0.5 μg/mL has been effective

• Detection conditions:

  • HRP-conjugated secondary antibody followed by chemiluminescence detection

  • Run under reducing conditions with appropriate buffer systems (e.g., Immunoblot Buffer Group 1)

What considerations are important for immunohistochemical detection of PDCD5?

For successful immunohistochemical detection of PDCD5:

• Sample preparation:

  • Formalin-fixed, paraffin-embedded sections are commonly used

  • Antigen retrieval is critical: use TE buffer pH 9.0 or citrate buffer pH 6.0

• Protocol optimization:

  • Antibody dilution: 1:50-1:500 for IHC applications

  • Incubation temperature and duration: 15 μg/mL overnight at 4°C has been effective

  • Detection system: Anti-Mouse HRP-DAB Cell & Tissue Staining Kit works well for visualization

• Controls and validation:

  • Positive tissue controls include human endometrial cancer tissue, human skin cancer tissue , and human stomach (specifically epithelial cells in gastric glands)

  • Include negative controls (primary antibody omission) to confirm specific staining

• Interpretation:

  • PDCD5 typically shows cytoplasmic staining in epithelial cells

  • Nuclear staining may increase during apoptosis

How can researchers validate the specificity of PDCD5 antibodies?

Validating PDCD5 antibody specificity is crucial for reliable results:

• Genetic validation approaches:

  • siRNA/shRNA knockdown: Compare staining between control and PDCD5-knockdown samples

  • CRISPR/Cas9 knockout: Create knockout cell lines as definitive negative controls

  • Overexpression: Use PDCD5-transfected cells as positive controls, as demonstrated in multiple studies

• Biochemical validation methods:

  • Peptide competition assay: Pre-incubate antibody with the immunizing peptide

  • Western blot: Confirm single band of expected molecular weight (14 kDa)

  • Immunoprecipitation followed by mass spectrometry identification

• Cross-platform validation:

  • Use multiple detection methods (WB, IHC, IF) with the same antibody

  • Compare results across different PDCD5 antibodies targeting different epitopes

How should researchers design experiments to study PDCD5's role in apoptosis?

When investigating PDCD5's function in apoptosis:

• Cell model selection:

  • Cancer cell lines (A431, HepG2, A498) have been successfully used to study PDCD5-mediated apoptosis

  • Consider the endogenous PDCD5 expression level in your chosen cell line

• Genetic manipulation strategies:

  • Stable overexpression: Create PDCD5-overexpressing cell lines using expression vectors and selection markers

    • Example: "The PDCD5 gene was stably transfected into the HepG2 HCC cell line (HepG2-PDCD5)"

  • Transient transfection: For short-term experiments

  • RNA interference: siRNA targeting PDCD5 has been used effectively

• Apoptosis induction methods:

  • Chemotherapeutic agents: Cisplatin sensitivity is increased by PDCD5 transfection

  • UV irradiation: PDCD5 enhances the cellular response to UV damage

  • Serum starvation or other physiological stressors

• Analysis endpoints:

  • Cell proliferation: MTT assay, EdU incorporation

  • Cell cycle analysis: PI staining and flow cytometry

  • Apoptosis markers: Annexin V-FITC/PI double labeling , caspase-3 activation

  • Protein expression: p53, Bax/Bcl-2, cleaved caspase-3

• Time course considerations:

  • Include early time points (1-6 hours) to capture initial events

  • Later time points (24-72 hours) for downstream effects

What approaches are effective for studying PDCD5 protein interactions?

To investigate PDCD5's interactions with other proteins:

• Co-immunoprecipitation (Co-IP):

  • "Endogenous co-IP assay showed that PDCD5 selectively interacted with HDAC3 among class I HDACs"

  • Can detect interactions with known partners like Tip60, HDAC3, and p53

• Fluorescence colocalization:

  • "Double fluorescence labeling showed the positive immunoreactive materials of PDCD5 were partly colocalized with MAP2, GFAP, CD34, p53, and caspase-3 in the penumbra areas in brain"

  • Provides spatial information about potential interactions

• Ubiquitination assays:

  • "Silencing of PDCD5 significantly reduced the HDAC3 ubiquitination"

  • Important for studying PDCD5's role in protein degradation pathways

• Functional validation:

  • Rescue experiments: "SGK1 expression was rescued by treatment with SGK1-flag"

  • Competitive binding assays to map interaction domains

• Chromatin immunoprecipitation (ChIP):

  • For studying PDCD5's role in transcriptional regulation with partners like Tip60

How can researchers investigate PDCD5's role in cancer biology?

When studying PDCD5 in cancer contexts:

• Expression analysis in cancer tissues:

  • "Decreased PDCD5 expression has been reported in various human tumors, such as breast cancer, hepatocellular carcinoma, lung cancer, gastric cancer, chronic myelogenous leukemia, and astrocytic gliomas"

  • Compare tumor vs. adjacent normal tissue expression

• Functional studies in cancer cell lines:

  • Proliferation: "Overexpression of PDCD5 significantly inhibited cell proliferation, induced cell cycle arrest at G2/M phase and apoptosis in A431 cells"

  • Invasion/migration: "PDCD5 overexpression can attenuate tumor invasion, EMT and the level of IGF-1 protein induced by TGF-β treatment"

  • Drug sensitivity: "The PDCD5 transfected cells showed higher sensitivity to cisplatin treatment than the HepG2-Neo cells"

• Mechanistic investigations:

  • "PDCD5 inhibits RCC cell proliferation and promotes T cell activation by silencing HDAC3 expression"

  • Study downstream pathways (HDAC3/miR-195-5p/SGK1 axis in renal cell carcinoma)

• In vivo tumor models:

  • "PDCD5 could significantly weaken the tumorigenicity of A498 cells, which could be reversed by SGK1"

  • Xenograft models with PDCD5-manipulated cancer cells

How can PDCD5 be used as a biomarker in disease research?

PDCD5's potential as a disease biomarker has been investigated:

• Rheumatoid arthritis (RA):

  • "PDCD5 expression was found to be significantly increased in RA patients in active status in comparison with healthy controls or those in stable remission status"

  • ROC analysis showed PDCD5 had better predictive value (AUC of 0.846) than anti-CCP, ESR, and DAS28 score for RA remission

  • Significant positive correlations between PDCD5 expression and clinical parameters (ESR, CRP, RF, anti-CCP, DAS28 score)

• Cancer prognosis:

  • Decreased PDCD5 expression in various cancers may correlate with disease progression and prognosis

  • "PDCD5 inhibits progression of renal cell carcinoma by promoting T cell activation"

• Neurological disorders:

  • "PDCD5 siRNA reduced the infarct volume, improved neurological deficits, improved cerebral blood flow (CBF), and reduced Evans blue extravasation" in stroke models

  • May have potential as a therapeutic target in cerebral ischemia

• Methodological considerations:

  • Standardize sample collection and processing protocols

  • Use multiple detection methods for validation

  • Incorporate appropriate reference genes for normalization

What are common challenges when working with PDCD5 antibodies and how can they be addressed?

Researchers may encounter several technical challenges:

• Multiple bands in Western blot:

  • Expected primary band at 14 kDa, but additional bands at 18 kDa and 20 kDa have been reported

  • Possible causes: post-translational modifications, protein isoforms, degradation products

  • Solution: Validate with positive controls, multiple antibodies, and include PDCD5-knockdown samples

• Distinguishing endogenous vs. exogenous PDCD5:

  • "We could not distinguish the endogenously expressed and exogenously delivered PDCD5"

  • Solution: Use epitope-tagged constructs (PDCD5-myc, as used in several studies)

• Low signal in immunohistochemistry:

  • PDCD5 expression may be low in some tissues

  • Solution: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) and detection systems

• Variability in expression across cell types:

  • PDCD5 expression varies substantially between tissues and cell lines

  • Solution: Include appropriate positive controls and normalize to housekeeping proteins

• Detection in apoptotic cells:

  • Apoptotic cells may detach and be lost during processing

  • Solution: Collect both adherent and floating cells for analysis

How can researchers accurately interpret changes in PDCD5 expression and localization?

For proper interpretation of PDCD5 data:

• Nuclear translocation events:

  • "PDCD5 protein could make use of clathrin-independent endocytosis to enter the cells and promote programmed cell death"

  • Nuclear accumulation of PDCD5 is an early event in apoptosis

  • Quantify nuclear/cytoplasmic ratio changes rather than just total expression

• Expression level changes:

  • Upregulation in response to apoptotic stimuli is expected

  • Downregulation in cancer tissues compared to normal tissues is common

  • Increased expression in inflammatory conditions like rheumatoid arthritis

• Correlation with functional outcomes:

  • Cell proliferation: "The HepG2-PDCD5 cells exhibited slower proliferation rates and high G2/M cell numbers"

  • Apoptosis sensitivity: "PDCD5 overexpression can inhibit growth and induce cell cycle arrest in HepG2 cells, and its also notably improves the apoptosis-inducing effects of cisplatin"

  • T cell activation: "Both CD3+ T cell proliferation and IFN-γ+ T cell proportion were promoted upon PDCD5 upregulation"

• Species-specific considerations:

  • PDCD5 is highly conserved across human, mouse, and rat

  • Many antibodies cross-react with multiple species, but species-specific differences in expression patterns may exist

What emerging techniques might advance PDCD5 research?

Several cutting-edge approaches could enhance PDCD5 research:

• CRISPR/Cas9 genome editing:

  • Create precise PDCD5 knockouts or introduce specific mutations

  • Generate tagged endogenous PDCD5 for live imaging

• Advanced protein analysis methods:

  • Proximity-dependent biotin identification (BioID) to map PDCD5 protein interaction networks

  • APEX2-based proximity labeling for subcellular localization studies

  • HDX-MS to study structural changes upon binding partners

• Single-cell techniques:

  • Single-cell RNA-seq to identify cell populations with differential PDCD5 expression

  • Single-cell proteomics to map PDCD5 protein levels across heterogeneous populations

• In vivo imaging:

  • Fluorescently tagged PDCD5 for real-time tracking in animal models

  • Multiplexed imaging to study PDCD5 in complex tissue microenvironments

• Therapeutic targeting approaches:

  • PDCD5-derived peptides for therapeutic applications

  • Small molecule modulators of PDCD5 activity or interactions

How might PDCD5 research contribute to developing novel therapeutics?

PDCD5's roles in apoptosis, inflammation, and cancer suggest therapeutic potential:

• Cancer therapies:

  • "Stable transfection of the PDCD5 gene can inhibit growth and induce cell cycle arrest in HepG2 cells, and its also notably improves the apoptosis-inducing effects of cisplatin"

  • PDCD5 restoration could sensitize resistant tumors to chemotherapy

  • Targeting the PDCD5-HDAC3-miR-195-5p-SGK1 axis in renal cell carcinoma

• Autoimmune disease treatments:

  • Modulating PDCD5's role in rheumatoid arthritis progression

  • Targeting T cell activation pathways involving PDCD5

• Neuroprotective strategies:

  • "Down-regulating PDCD5 can protect the brain from ischemic damage by inhibiting PDCD5-induced apoptotic pathway"

  • PDCD5 siRNA showed protective effects in stroke models

• Biomarker applications:

  • "PDCD5 may be used as a novel biomarker for the prediction of RA incidence and remission"

  • Patient stratification for personalized medicine approaches